Information for professionals

Quit education Client groups Order resources
Skip to main content

GP guide algorithm references

References for the Helping patients to stop smoking: a guide for general practitioners pharmacotherapy algorithm.

  1. Leung, L.W.S. and Davies, G.A., Smoking Cessation Strategies in Pregnancy. J Obstet Gynaecol Can, 2015. 37(9): p. 791-797.
  2. Turner, E., et al., Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. Nicotine Tob Res, 2019. 21(8): p. 1001-1010.
  3. De Long, N.E., et al., Is it safe to use smoking cessation therapeutics during pregnancy? Expert Opinion on Drug Safety, 2014. 13(12): p. 1721-1731.
  4. The Royal Women's Hospital, The Pregnancy and Breastfeeding Medicines Guide. 2019, Melbourne: The Royal Women's Hospital.
  5. Lindson, N., et al., Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2019. 4(4): p. CD013308.
  6. Bolt, D.M., et al., Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol, 2012. 80(1): p. 54-65.
  7. Shah, S.D., et al., Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003), 2008. 48(5): p. 659-65.
  8. Trivedi, D., Cochrane review summary: Pharmacological interventions for promoting smoking cessation during pregnancy. Prim Health Care Res Dev, 2013. 14(4): p. 327-9.
  9. The Royal Australian College of General Practitioners, Supporting smoking cessation: A guide for health professionals, in 2nd edition. 2019, RACGP: East Melbourne, Victoria.
  10. Heatherton, T.F., et al., Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict, 1989. 84(7): p. 791-9.
  11. Stead, L.F., et al., Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2012. 11: p. CD000146.
  12. Coleman, T., et al., Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev, 2015(12): p. CD010078.
  13. Benowitz, N.L., et al., Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med, 2018. 178(5): p. 622-631.
  14. Joseph, A.M., et al., The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med, 1996. 335(24): p. 1792-8.
  15. Hubbard, R., et al., Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control, 2005. 14(6): p. 416-21.
  16. Woolf, K.J., et al., Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol, 2012. 110(7): p. 968-70.
  17. Reid, R.D., Mullen, K.A. and Pipe, A.L. Systematic approaches to smoking cessation in the cardiac setting. Curr Opin Cardiol, 2011. 26(5): p. 443-8.
  18. Pfizer Australia Champix (Varenicline) [Product Information]. March 2019.
  19. Aspen Pharmacare Zyban SR (Bupropion) [Product Information]. March 2020.
  20. Polosa, R. and Benowitz, N.L. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci, 2011. 32(5): p. 281-9.
  21. Gilpin, E.A., K. Messer, and J.P. Pierce, Population Effectiveness of Pharmaceutical Aids for Smoking Cessation: What is Associated with Increased Success? Nicotine Tob Res, 2006. 8(5): p. 661-669.
  22. Hartmann-Boyce, J., et al., Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev, 2018. 5(5): p. CD000146.
  23. Pipe, A.L., et al., Smoking cessation and the cardiovascular specialist: Canadian Cardiovascular Society position paper. Can J Cardiol, 2011. 27(2): p. 132-7.
  24. New Zealand Government Ministry of Health New Zealand guidelines for helping people to stop smoking. 2014.
  25. Roddy, E., Bupropion and other non-nicotine pharmacotherapies. BMJ, 2004. 328(7438): p. 509-11.
  26. Hughes, J.R., et al., Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2014. 2014(1): p. CD000031.
  27. US Department of Health and Human Services, How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. A report of the US Surgeon General. US Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Editor. 2010, Office on Smoking and Health: Atlanta, GA:US.
  28. Stead, L.F., et al., Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 2016. 3: p. CD008286.
  29. Chang, P.H., et al., Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC public health, 2015. 15: p. 689-689.
  30. Cahill, K., et al., Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016. 2016(5): p. CD006103.
  31. Australian Medicines Handbook, Drugs for nicotine dependence, in Australian Medicines Handbook. 2020, Australian Medicines Handbook Pty Ltd: Adelaide.
  32. Koegelenberg, C.F.N., et al., Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation: A Randomized Clinical Trial. JAMA, 2014. 312(2): p. 155-161.
  33. Ramon, J.M., et al., Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Medicine, 2014. 12: p. 172-172.
  34. Cahill, K., et al., Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 2013(5): p. CD009329.

Sign up to our newsletter to receive the latest news,
launches and policy updates from Quit.